Moreover, an in-depth characterization of P2Y12R expression in tumor cells is necessary to enlighten potential novel direct therapeutic activities of P2Y12 antagonists. On the other hand, further findings on P2Y12R activity in non-malignant cells should be useful, since they could help monitoring the possible adverse effects caused by the systemic administration of P2Y12-targeted drugs.